EGFR and small cell lung carcinoma: The 2020 Chinese Society of Clinical Oncology (CSCO) Guidelines for the Diagnosis and Treatment of Small Cell Lung Cancer recommend standard SCLC chemotherapy plus continued original EGFR-TKI as the treatment regimen for patients with transformed SCLC (Class III evidence, Class III recommendation) (7).